These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 39215346

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. PSMD14 stabilizes estrogen signaling and facilitates breast cancer progression via deubiquitinating ERα.
    Yang P, Yang X, Wang D, Yang H, Li Z, Zhang C, Zhang S, Zhu J, Li X, Su P, Zhuang T.
    Oncogene; 2024 Jan; 43(4):248-264. PubMed ID: 38017133
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
    Basak P, Chatterjee S, Bhat V, Su A, Jin H, Lee-Wing V, Liu Q, Hu P, Murphy LC, Raouf A.
    Cell Physiol Biochem; 2018 Jan; 51(4):1518-1532. PubMed ID: 30497079
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
    Bostner J, Alayev A, Berman AY, Fornander T, Nordenskjöld B, Holz MK, Stål O.
    Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
    [Abstract] [Full Text] [Related]

  • 9. Epigenetic reactivation of estrogen receptor-α (ERα) by genistein enhances hormonal therapy sensitivity in ERα-negative breast cancer.
    Li Y, Meeran SM, Patel SN, Chen H, Hardy TM, Tollefsbol TO.
    Mol Cancer; 2013 Feb 04; 12():9. PubMed ID: 23379261
    [Abstract] [Full Text] [Related]

  • 10. MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators.
    Ljepoja B, García-Roman J, Sommer AK, Wagner E, Roidl A.
    Breast; 2019 Feb 04; 43():31-38. PubMed ID: 30415143
    [Abstract] [Full Text] [Related]

  • 11. Extranuclear ERα is associated with regression of T47D PKCα-overexpressing, tamoxifen-resistant breast cancer.
    Perez White B, Molloy ME, Zhao H, Zhang Y, Tonetti DA.
    Mol Cancer; 2013 May 01; 12():34. PubMed ID: 23634843
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The ubiquitin ligase RNF181 stabilizes ERα and modulates breast cancer progression.
    Zhu J, Li X, Su P, Xue M, Zang Y, Ding Y.
    Oncogene; 2020 Oct 01; 39(44):6776-6788. PubMed ID: 32973333
    [Abstract] [Full Text] [Related]

  • 15. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
    Zhang X, Zhang B, Zhang P, Lian L, Li L, Qiu Z, Qian K, Chen A, Liu Q, Jiang Y, Cui J, Qi B.
    PLoS One; 2019 Oct 01; 14(5):e0217181. PubMed ID: 31120927
    [Abstract] [Full Text] [Related]

  • 16. Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells.
    Gao P, Wang X, Jin Y, Hu W, Duan Y, Shi A, Du Y, Song D, Yang M, Li S, Han B, Zhao G, Zhang H, Fan Z, Miao QR.
    Breast Cancer Res; 2018 Sep 12; 20(1):112. PubMed ID: 30208932
    [Abstract] [Full Text] [Related]

  • 17. Loss of pigment epithelium-derived factor: a novel mechanism for the development of endocrine resistance in breast cancer.
    Jan R, Huang M, Lewis-Wambi J.
    Breast Cancer Res; 2012 Nov 14; 14(6):R146. PubMed ID: 23151593
    [Abstract] [Full Text] [Related]

  • 18. USP9X downregulation renders breast cancer cells resistant to tamoxifen.
    Oosterkamp HM, Hijmans EM, Brummelkamp TR, Canisius S, Wessels LF, Zwart W, Bernards R.
    Cancer Res; 2014 Jul 15; 74(14):3810-20. PubMed ID: 25028367
    [Abstract] [Full Text] [Related]

  • 19. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
    Imachi H, Murao K, Dobashi H, Bhuyan MM, Cao X, Kontani K, Niki S, Murazawa C, Nakajima H, Kohno N, Yamashita H, Iwase H, Hayashi S, Ishida T, Yamauchi A.
    Breast Cancer Res Treat; 2010 Jul 15; 122(2):395-407. PubMed ID: 19847644
    [Abstract] [Full Text] [Related]

  • 20. VAV3 mediates resistance to breast cancer endocrine therapy.
    Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA.
    Breast Cancer Res; 2014 May 28; 16(3):R53. PubMed ID: 24886537
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.